Diplatin, a Novel and Low-Toxicity Anti-Lung Cancer Platinum Complex, Activation of Cell Death in Tumors via a ROS/JNK/p53-Dependent Pathway, and a Low Rate of Acquired Treatment Resistance

• Main Authors: Xixi Lin (Author), Yongliang Jia (Author), Xinwei Dong (Author), Jian Shen (Author), Yachao Jin (Author), Yanyou Li (Author), Fang Wang (Author), Eitan Anenberg (Author), Jiancang Zhou (Author), Jianping Zhu (Author), Xiaoping Chen (Author), Qiangmin Xie (Author), Yicheng Xie (Author)
• Format: Book
• Published: Frontiers Media S.A., 2019-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Platinum-based drugs prevail as the main treatment of lung cancer; this is caused by their relative effectiveness despite known side effects, such as neurotoxicity. The risk reward of the treatment and side effects is confronted when dosage is considered and when resistance to treatment...